SENSEX NIFTY
Apr 05, 2012, 10.58 PM IST | Source: CNBC-TV18

Biocon expands its R&D facility in Bangalore

Bio-pharma major Biocon on expansion mode.

Kiran Mazumdar-Shaw, CMD, Biocon

Bio-pharma major Biocon is on an expansion mode. The biotech major plans to invest close to Rs 100 crore on its new research and development center located in Bangalore, with a window for future investments going up to Rs 200 crore in next few years.

Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
 
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.

Biocon stock price

On December 19, 2014, Biocon closed at Rs 433.85, down Rs 0.4, or 0.09 percent. The 52-week high of the share was Rs 553.70 and the 52-week low was Rs 408.05.


The company's trailing 12-month (TTM) EPS was at Rs 20.14 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 21.54. The latest book value of the company is Rs 120.89 per share. At current value, the price-to-book value of the company is 3.59.

Set email alert for

ADS BY GOOGLE

video of the day

Rupee weakness modest, see yields at 7.60% in Q1: Deutsche

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.